The government alleged that at the direction of Piero Anversa, MD, who ran the facility, and two other researchers, the stem cell lab included false scientific information in applications submitted to NIH to obtain grant awards.
After learning of the possible research misconduct, Brigham and Women’s disclosed its concerns to the federal government, according to the DOJ.
“Individuals and institutions that receive research funding from NIH have an obligation to conduct their research honestly and not to alter results to conform with unproven hypotheses,” said Acting U.S. Attorney William D. Weinreb. “Medical research fraud not only wastes scarce government resources but also undermines the scientific process and the search for better treatments for serious diseases. We commend Brigham and Women’s for self-disclosing the allegations of fraudulent research at the Anversa laboratory, and for taking steps to prevent future recurrences of such conduct.”
More articles on legal and regulatory issues:
Ex-WellCare CEO and CFO face deadline to repay $26M from fraud scheme
Shuttered NC hospital’s settlement over improper layoff notifications receives preliminary approval
Michigan hospital pays $791k to resolve false billing allegations
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
